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Because physicians have traditionally rlinsidered heart failure to 
be B hemodynamir disorder. they have described thp syndrome of 
heart failure using hemcdynamic onrrpB and have designed 
treatment strategtes tocorrect he hemodynamie d rangements of 
the disease. However. althoueb ?modvnamic abnormalities mav 
explain the symptoms of h&t failure; they are not sufficient lb 
e&tn tbr pm~rw~w of heart failure and, ultimately. the death 
of the patient. Therapeutic interventions may impr& the hemo- 
dynamic status of patients hut advenely sSct their tong-term 
wtcomc. These findings have mind questk zbnut the validity 
of the hemmiynamic hypothesis and suggest hat alternative 
I-iiliiimtdsms muri piay a primary reie in adnneing the disease 
prUCfS. 
Sewal lines of evidenrc snuggest that neurohormonal mecha. 
oisms play a central mle in the progression of heart failure. 
You do one expenmem io medicine 10 convince youraetl. 
the” 99 mow to convince lerc. 
-Alphonrc Raymond Dochez 
For the last 40 years, physicians have viewed the syndrome 
of congestive heart failure primarily as a hemodynamic 
disorder. When we learn about the pathophysiology of heart 
failure, we are taught about prelcal. aft&ad a% cardiac 
contractili!y and are told how these phyuoloaic variables 
al&t cardiac performance. When we hi&s ihe treatment 
of heart failure. WC think in terms ofcardiac output. pulmo- 
nary capdlary wedge pressure and systemic vascular resis- 
tance and try to miior our treatment o correct these hemo- 
dynamic derangements. When we want to delineate the 
prognosis of patients with heart h~lure, we measure cardiac 
size and left ventricular ejection fraction: and we believe that 
attempts to improve these variables will prolong life. Be- 
cause the principal tools of cardiology have traditionally 
been the measurement ofpressure, volume and flow. it is not 
Activation of the sympathetic IIEIV~US *gstem and rain. 
angiotensin system exerts B direct deleterious &a on the heart 
that is independent of the hzmodynamic actions of these mdoge- 
nous mechanisms. Therapeutic interrentions that block the effects 
of these nrurohormonal systems Favorably alter the natural hii- 
tory of he,wl failure, and such benefits cannot be wptained by the 
etTert or these treatments on cardiac contractility and ejection 
fraction. Conversely, pharmacotr$c agents that adversely Mu. 
ence aeurohormonrl ystcms in heart failure may incresle cardiu- 
va,wular morbidity and mnorfdlity. even though they exert favor. 
able hemadynamic effects. These observations support the 
formutation ot a neurohormonrd hypothesis of heart failure and 
provide the basis ior the devdopmer.t of nowi tberapeuttc swat. 
E&I in the next decade. 
surprising that we have defined heart failure by using these 
hcmodynamic concepts. 
To an important degree, this hemodynamic viewpoint has 
helped us understand and alleviate the swn!avns of heart 
fail&c because hemodynamic abnormalit& are probably the 
major caue of disabilitv in this disorder. Althoueb the 
p&se manner in which ventticukw dysfunction leads to 
symptoms remains unclear, the cardinal clinical manifesta- 
tion of heart failure is an inabilily to tolerate exercise. and 
exercise capacity appears to be limited by a combination of 
cenlral and peripheral hcmodynamic factors. Symptoms of 
heart failure develop either when pulmonary venous pres- 
sure increases to critical values or when blood Row to 
exercising skelwl mwlc is severely limited (l-4). A pre- 
cise separatwn of these central and peripheral hemodynsmic 
factors is very difficult because cardiac fun&w is the major 
determinant of peripheral perfusion and the peripheral cir- 
culation is a major determinant of ventricular perfornzmce 
(5). Nevertheless. because B close relation exists between 
specific hemodynamlc abnormalities and the impairment of 
exercise tolerance in heart failure (l-4), drugs that correct 
the hcmodynamic abnormalities in the disease (either by 
increasing cardiac contraclility or decreasing peripheral 
vasoconstriction) generally lead to an amelioration of the 
clinical disability of these paiients. 
However, beart failure is not only disabling, it is also 
progressive. Over a period of months io years, cardiac 
performance deteriorates, exeretse capacity declines. pe- 
ripheral organ function become? mcreaGngiy comproo%eJ cnrd:uc tunc~~un m the normal heart. a similar mcreze m 
and fluid rctcmion emerge5 a5 a ma~“r clmat problem. ioadinp c”nd,r,ons adversely afiects the function of the 
Although the rote “fprogressiw yBric5. all memh\tatw~ “f !:::irng heart ‘Tlxs difference i\ related to an alteration in the 
the syndrome worsco over time. wcn lhooph powerful re\pon‘~\cnc\\ And wnceptihility of the noninjured heart to 
medications are added or admmistercd in mcrea4ne do\e+ strew after the loss of a \ienificant quantity of contractine 
but with decreasing efficacy. ‘The coow of tke d&c may 
be in,erru,xed by b,,ef per,od> of re\poc. bo, mevcably ihe 
parient experiences rubs~anl~al dsabdlly. a recur~nr need 
for ho;pitalization and cmergcncy care and. uamateiy. 
death. No matter how stable the condition of 08 indwdual 
patient ma) appear initially. the underlying diwse 
progresw Respire the most careful anentian to the hemo- 
dynamic and clinical abnormalities of the syndrome. moot 
ritients who have heart failure will die of heart foilore. 
ad&dstmtidn of a cardiotoxic drug or after the recurrence 
factor that i; re&msible for symptoms. namely. hrmady- 
of myocardtal intarc:ma. io most patients. however. hext 
namic stress. However. as we wili oemonstrate in this 
failure progwwes we” though !ke primary cause of left 
review, the results of recent studies do not support the 
ventricular dysfunction is no longer prese :t ur active. Under 
kemadynamic hypothesis, but instead indicate that akerna- 
these circumstances. heart failure advances because the 
tive mechanisms most play a primary role in advancing the 
Although we believe that hemodynamlc factors play an 
essential role in caosmg the symptoms of heart failure. ae do 
original cause triggers endogeoous mechdnisma that (“ncc 
disease process. 
not understand the factors responsible for progewon of the 
disease. Undoubtedly, heart failure may progrchs because of 
set into motion) lead to the :nei;“rable ia. tif myocardlal 
persistence or recurrence of its primary ~aure This concept 
exolains wbv heart failure worseos durine the continued 
cells. The precise notore of tnese endogeoous mechanisms 
has not been defined. but for the lest 40 years. cardiclqists 
have assumed that the endogeoous facwr tkat X: responsible 
for disease aroeression in heart failure is identical t” the 
myocardzum. The normal heart cat utilize an mcrease in 
prclmd I” enhance rysrohc ejection (Frank-Stw!ing mecha- 
decrease in ventricular functiow Hence. a drug that reduces 
However. hecause the functional consequences of hemo- 
mrm) and h;l\ do imrin5ic ability to “wrwme ao mcreace in 
afterload by augmenting contractde force lkomeometnc 
dynamx ~trcss are readily revened when rhe aress is 
ventricular wall stress might not only improve cardiac per- 
autore~~daoon~ (61. However. in the failing heart, increases 
in pre!old do n”t enhance )yst”lic performance lbecause the 
redwed. an increase in cvdiac preload and afterlwad cannot 
formance and symptoms, but might also retard the pr”grG- 
Frank-Starlmg curve IS both depressed and flattened) and the 
abnormal myocardwm cann”t increas: contractility in re- 
explain the inexorable progression of heart failure. Hence. a 
we detenoration of cardiac woctore and funxion Land 
sponse t” an increase in afterload (51. Hence. any mcrease an 
imer\ m rhe fading heart will further impair cardiac function 
key assumption of the hemodynamic hypothesis is that a 
prolong life (9). Importantly, because ho:h positive isotropic 
and !hus any intervention that ameliorates loading condi- 
tt”ns m hr2i: Liiure will augment cardiac performance. This 
prolonged mcrease in hemodynamic stress in the impaired 
agents and peripkelal vasodilators reduce reoiricu:ar watt 
pnnciple explains why drugs that reduce ventricular wall 
stresh. it should not matter how kemodynamic improvement 
\IKIF gcncr41y improve the clinical rtatos of patients with 
Ibear! leads I” an irrewrsihle rinrctwal deterioration of 
is ac$eved. Accordinp. to the kerndynamic hypothesis, 
heart fdilurc. 
ventrulor function. Recent stud& 17.8) have shown that 
sustained increases in cardiac ~“loroe and pressure after 
acute myocardial injury can caose Trogresrive str~ctoral 
remodeling that is gaerally accompanied bjj a penoanent 
The Hemodynamic Hypothesis of 
Disease Progression 
According to the kemodynamic hypothesis. heart bilure 
progresses because hemodynamic stresses that are triggered 
by the initial injury t” the heart exert a deleterious effect on 
the circulation. Any loss of viable myocardiom is inevitably 
followed by a” increase in enddiastobc pressure and vol- 
“me, as the heart attempts to maintain stroke volume ot a 
reduced ejection fraction. However, this increase in loading 
conditions (preload and afterload) constitutes an important 
hemodynamic stress for patients with hear! failure and may 
adversely affect both the functional and the structural inleg- 
rity of the noninjured myocardium. 
Dtoing shon periods of time, the consequcnc~s of hemo- 
dynamic stress are primarily functional. Whereas an in- 
crease in preload and afterload leads to a” improvement in 
both types of drug shouid retard the st”&al and functional 
consequences of hemodynamic stress and thereby exert a 
favorable effect on the natural history of heart failure. 
Testing the Hemodynamic Hypothesis 
Stud& with vasodilator drags. The first clinical test of 
the hemooynamic hypothesis was the first Veterans Affairs 
Heart Failure Trial IV-HeFT Trial) 110). Begun in 1978. the 
principal aim of this study was I” determine if drugs that 
reduce wall slress would reduce the risk ofdisease progres- 
sion and thus prolong life in par:ents wirh heart failure. To 
trbl &is posbibiiity, ibr i”ve3uig*i”r~ urcd the uoiy wil:j 
active va~odilators available to them in the late 1970s: 
prozosrn and a combination of hydralazine and isosorbide 
dimtratc. Borh drug regimens were hemodynamicaliy eifec- 
live and produced similar decreases in ~:entricular prcload 
and afrerload (t 1.121. Thus. ifthc hcmodynamic hypothesis particularly if the Qoaitwe inotropic agent also ddatec pertph- 
was true. both vasodilators should have produced hvorable eral blood VCECCIS. Such a combination of inotrooic and 
changes in the natural history of heart f&we. vasodilator effects iz particularly charactertwic of positive 
Interesttnclv. the V-HeFT trial showed that one-but not inotropic druss that act bv mcreasinc intracellular cyclic 
greatest decrease in blood pressure should haYe been zxw 
both-of the~;asodilator treatments was associated with a 
reduction m the mortality rate in patients with chronic heart 
ciated wtb the iwest mortality rate. Such a findinc would 
failure. On the basis of the bemodynamic hypoiheris. the 
successful vaiodilator regimen <hould have been the treat- 
ment that produced the greatest peripheral vasoddation and 
tbur the most marked reductton in wall htren. Unfortu- 
nately. neither systemic vrlscttlar resistance nor wall strer, 
we5 measured in the V-HeFT study: the only estimate of 
loadin conditions was systemic blood Qrew~re. Thus, we 
would have expected that the ,reatment that Qroduccd the 
adeno&ne m&oQhosQh& CAMP1 <for example. deta- 
agonist, and phosphodicsteraae inhibitors). These drugs 
produce marked hemodynamic eRects in patien*n wth 
chronic hear! failure 121,221. and long.term treatment with 
the phosphodiesterase inhibitor milrinone reducer both ven- 
lricular wall stress and mortality itt an experimental model of 
heart failure in the rat (23.24). The results of this experimen- 
tal study support the hemodynamic hypothests. 
be& borne out by-the re&ts of controlled cl&xl trials. 
Beta-aeonists and Qhosnhodiesterase inhibitors have not 
Unfortunately. the expectations of the hemodynamic 
hypothesis with respect to Qositive inotropic drugs have not 
be %rikingly similar to the resuils of trials of vttsodii&xs in produced consisten~clin~cal benefits. and long-term therapy 
patients with severe hypertension (131. in whom the reduc- with these drugs has been associated with an increase (rather 
tion of blood pressure led to a ~L~UCII’JP in the risk of fatal rhan a decrease1 tn mortali!y !25). In the Prospective Ran- 
and nonfaardl cardiovascular events. However, in the 
dintt:x:r (which exerted no imporlant hypotensive eiTect~1 
reduced mortality by 28% 1101. This ttpparenl discordance 
between the bemodynamic and prognostic elfccts of vasodi- 
V-HeF’I study. prazosin produced the greatest decrease in 
later therapy remained unexplained. 
systemic blood preraure but faded to reduce mortality. In 
contrast. the combination of hydraiazioe and isororhide 
particulatly marked in patients who had the most ad&d 
domized Milnnone Survival Evaluation (PRbMISE trial) 
hemodynamic and clinical abnormalities. that i$. those with 
cidjs IV rgmptoms 
(261. treatment with milrinone war associated with a 28% 
increae in all-csuse mortality and a 34% increase in the risk 
of cardiovascular death. The risk of milrinone theraw war 
Hence. the predictions of the hemodynamic hypothesis 
have nor been atpported by clinical e~psr;snce with thera- 
peutic interventions for hart failure. Drugs that produce 
hemodynamic benefits. either by increasing contractility or 
by decreasing ?iriphernl vas~ronstrirtion,.have not favor- 
ably altered the natural history of heart failure and many 
have had deleterious effects on survival. As a result, we (27) 
and othen have begun to formulate alternative theories 
about how and why heart fadure progresses. Such a reeval- 
uation ::I- ied to the formulation of the neurohormonal 
hypothesis of heart failure. 
Similarly, among the mart p&lar vasodilator drug; used in 
clinical medicine are the calctum channel blocking drugs, 
and their administration to patients with heart failure has 
A stmilar discordance be!wcen the hemodynamic and 
proenostic cflects of treatment has been noted in controlled 
been reported to produce systemic vasodilation and hemo- 
trials with other vasodilator drugs. One of the most potent 
vasodilzlor dntes wed io clinicel medicine is minoxidil. and 
dynamic benefits (16). Houtever, in controlled clinical trnds 
tts administration to patients with heart failure rew!!s in 
marked incred~es 19 cardiac output and lefl ventricular 
(17-20). patients lieated with verapamil. nifedipine and 
ejection fraction (14.15). Yet, in a controlled trial (15) will! 
the drug, patients treated with minoaidil required more 
diltiazem niere at higher risk of worsening heart failure and 
diuretic agents. erpenenccd more angina and ventricl;!ar 
arrhythmias and wete at higher risk of worsening heart 
failure and death than were patients treaied with clacebo. 
cardiovascular death than were patients not treated with 
these drugs. These expenences suggest that hemodynamic 
improvement does not invariably lead to a favorable change 
in the natural history of heart failure. 
the hcmodynamic abnommlities of heart Failure or because 
neurohormonal activation exerts a direct toxic e&cl on the 
myocardium. 
The Neurohormonal Hypothesis 
According to the neurohomtonal hypo:hesis, heart failure 
pR78WSSeS because endogenous neurohornonal systems 
that are activated by the in&l injury lo the heart exert a 
deleterious effect on the circula1io.t. Such an effect may 
occur either because neurohormonal activation exacerbates 
Studies with positive isotropic drugs. According to the 
hemodynamic hypothesis, drugs that produce hemodynamic 
benrE:s ty iqx~ing cardiac contractility should favotdly 
inthtence the natural history of Seari fatlure. A decrease in 
conrraculity 1s generally re&gmred to be the rundamenlal 
defect B tbr lailing heart. and any drug that improves 
systolic ejtc:ion ~uould also reduce ventricular wall stress. 
Activation of the sympathetic nervous system and renin- 
angiotensin system can have adverse hemodynamic conse- 
quences in bat Bdure because both systems enhance 
systemic vasoconstriction and promote the retention ot 
sodium and water. Both of these hemodynamic derange- 
ments may further increase neurohormonal activity because 
they increase atrial distension and may thereby (aver time) 
exacerbate the degree of secondary baroreceptor dysfunc- 
tion ,281. Not onI> are patwn with bean :.Glurc ru\ccp!iblc 
to the adverse effect- of nrurohormonai \y\rem\. hut they 
are resistant to their bcncficml hemodynnmlc ~ctmn~. 
Whereas sympathetic activity stlmuliw~ cardiac contractd. 
ity in the normal heart, the motropic effect, of rndogencu\ 
catecbolaminer are blunted m the Failing bsart ,291 Conrc- 
quently. by potenliating each utbcr., rxl~crx e%zct~. the 
hemodynamw and neurohormonal abnormalitw of bear: 
f&lure may interact to accelerate the rdv of progrewon of 
the underlying disease. 
However. P ne!lrohormonal acti\Gt! ad\ rnely alfectcd 
heart failure only because oi 1t5 dclc~cnou~ hemodynamlc 
eiiects. the neurohormonal hypothew would merely be a 
sunpIe modification of the hemodynamic model of dww 
progression. Thus, a key a~sumptmn of Ihe nrurohormonal 
lbypnthesis ix that prolonged achw!wn of the rympathetw 
nervous system and the rentn-angmtenw~ system exert\ a 
direct adverse effect on the heart rn&pr~~r’r~m of the hsmo- 
dynamic acttom of these systems. Recent ~ud1e5 ~!rozg!) 
ruppott this assumptmn. High con~entritt~onb ofnorsouteph- 
tine and angiotensin exert direct detetenous effects on 
myocardial cells (30.31). and interference with the acuon~ oi 
these hormones can prevent cell injury and diceae prows- 
sion in experimental modclr of left ventricular dysfunctiw 
,9.24.30-321. According to the neurohormonal hypothew. 
these findings should be replicated in the climcal setting. 
rcl.ad pnmanly to ~be~r neurohormonal xtwx First. in 
COUSEUSUS. enalannl reduced the mona!it, rate onmar- 
ili ‘n patrco,\ who had the greatest neuroho~~onel’octaa- 
rion iat the !wne of initiation oftherapy. In Contras. enalapn! 
produced fen prognostic benefit\ m patients wvlth low CIICU- 
lalmp !e\ci\ of norepmephrme or antiotensin before tr~tt- 
ment. e\en ihough the drug wa\ Ml hcmodynamicatly 
effectwe I” ruch paients 1371. 
Second. ,n another Veterai Affairs Heart Fadwe Tnal 
IV-HcFT I!1 138). theeffectson mortality of rnalapril (adrug 
znh i;iborrh,e vawdilator and neurohommnal cffccts1 were 
compared x~tb rhosc of a combmation oi hydralarine end 
w\orbvJe dmitratr (drugs with beneficial hemodynamic but 
wnhout favorable neurohormonal effects). Recauw of di&r- 
cnw in the neurohormonal profile of the tno treatments. 
tbi< study provided a umque opponuntty I I RS and criti- 
~allv evaluate the hemodynamic and neurohormonal hypoth- 
ew Compared with enalapril. the hydralarinc-mtrate com- 
bioatiw wn more effect% bemodynamically because leit 
ventncular ejection ixtion mcrcased moie dunng hydnta- 
Line-litrate therapy ,3X). rhw dirierrnce in ejecrion inaction 
ma! have been related to a more pow&d vasodilator effect 
of the direct-acting vasodilators or P’ diRercoca ia the 
effects of !hc !:i’o ircxments on cardiac contrac:ili!y. ah;ch 
increases with hydralazine (39.401 but decreases with enal- 
april (41). In contraa. enalapril had more favorable ncnro- 
hormonal cLcts in (his srudv because onlv the convertma 
enzyme inhibitor pr duced adecrease m pl&nanorepincph- 
rine 1421. Which treatment orolonred life? After 2 wari of 
follow-up. rhe mortaiity r&c wi5 signilicantly lower in 
patient< treated with enalapril than in those whnreccia:d the 
combination of hydralazine and isosorbide dinitra:e (38). 
Furthermore. as in CONSENSUS. rhe difference between 
the two treatments was greatest in patient5 with the greatest 
neurohormonat activation ot the time of initiation of therapy 
,431. Both observations strongly suppon the neurohomtonal 
hypothesis. 
Testing the Neurohormonal Hypolhesis 
Studies with angiotensin-eonvorting enzyme inhibitors. 
‘The first clinical te5t of the neurohormonal hypothesis was 
!hr Cooperative North Scandmavian Enalaptil Survival 
Study (CONSENSUS) (33). The primary aim of this study 
was to determine whether a drug that interferes with the 
actions of the renin-angiotensin system (enalapril) would 
reduce the risk of disease progression and thus prolong life in 
patients with 5evere (class IV) heart failure. In this study. 
enalawil reduced total nwtalitv by 4ffh at 6 month5 and by 
31% ;t I yea;. The results of CONSENSUS ,m patients ii 
cl%55 IV) were recently confirmed by the Studies of LeA 
Ventricular Dysfunction (SOLVD) trial ,341. whtch showed 
that enalapril reduced both total mortalty and the risk of 
wonenin~ heart failure in patients with.class II and 111 
5ymptoms. Similarly favorable effects an disease progres- 
sion and mortality have been observed with other converting 
enzyme inhibitors (for example. captopril) (33.361. 
Do lhe resrdts of rhc CONSENSUS snd SOLVD wink 
/w”vr the newohornmnal hyporhcsis? Because captopnl and 
enalapril exert effects both on the penpheral va~culature and 
on neurob--mnal activity, it is possible thilt the benefits of 
these drug, are related to their peripheral vasadilator e5ects 
(which would favor the hemodynamic model) and not their 
in!erference with the rain-angiotensin system (which would 
favor the neurohormonal model) (8). However, two lines of 
evidence strongly favor the contention that the beneficial 
eifecls of the convening enzyme inhibitors an survival are 
Studies with betasdrettergic blockit.:: dntgs. Additional 
evidence favoring the neurohormanil hypotheses has 
emerged irom clinical srudies with dnirs that block rhc 
txtivity of the sympathetic fiervous system. ror many yea, 
physicians believed that beta-adrenergic blockers were can- 
traindicated in patient5 with chronic heart failure hecauce 
the cympathetic nervo~5 system provided important short- 
term support for the failing heart (44). Such a belief was 
consistent with the prevailing hemodynamic hypothesis. 
which implied not only that drugs with favorable hemcdy- 
namx effects should be used in heart failure, but also thar 
drug5 wrh advene hemodynamic effects should be avoided 
in patients with advanced left ventricular dysfunction. How- 
ever. since the realization that long-term activation of the 
sympaiinic IWYVU~ system ay be deleterious to the heart 
(451. there has been increesmg mterest ID the ore of beta- 
blockers m the treatment of heart Sadure (46). 
The recent finding that beta-blockers may cxen favorable 
(raiher than adverse) et&as in patteas with chronic hart 
failure has provided strong sopport lor the oeumhormonal favorably than the cyclic AMP-dependent positive inotrapic 
hypothesis. &vcral small hut well contmlled clinical trmls agents t26.56.58). In cootrast. the hemodynamic hypotheses 
147-49) hwe ihown that beta-blacken can allewatc s~mo- would have oredictcd suvcrior clinical results wth the cyclic 
AMP-depenbent agent\ iw~se both the be,*-a@tdand 
the phoaphodics;eraae mhibitors at&t cardiac contraetdity 
and the perapheral vasculature more favorably than digitali*. 
toms and iroprove ventricuiw fanctwn in patient\ ‘wi;h 
idiopathic dilated cardiomvopathy. In addi:ioo. subgroup 
aoalyses of large scale :rlil!s 150) have shown that heta- 
blockers con reduce moriahty in patients with Irfi ventrico- 
IN dysfunction we to iwxtnic ibeart discasc. As with the 
canvertmg enzyme mhibitora. the greatest benrtils of beta- 
blockers are apparen: in patients with the greatest activation 
ofthe s;z;_,:bt’ic r,er\o:; sys:;m a: ihe ttan ofthcrapy. .I> 
reflected by pretreatment heart rate or circulating norcpi- 
nephrinc level, (51.521. 
e&c+ ?f ~B)CIUIP. chkel blockers in chronic heat fadurc 
Studies with positive and negative inctrapic agetats. If the 
hemodynamic hypothesis is correct. we might expect drogr 
(16-20). However. the restdts of controlled clinical trials 
with positive inotropic c~ccts to be benrficia! m heart faihoe 
and drugs wth nrg~tive inotroplc action. 
indicate that phosphooiesterare inhibitors !which enhance 
J have deleterious 
etTec!s. Such a concept has ilccn used to explain the adverse 
Conclusions 
mortality. Similarly. although the results of most controlled 
studies appear to refute the hemodynamic hypothcsts, tP_ 
Based on the studies cited in rhls review, can we conclude 
that there IS r~dFc~cnt cwience I,, accept the neurohornonal 
evidence is not sufficient to completely reject an important 
hypothesis and reject the hemodynamic hypothesis of heart 
faihw? Although the results of controlled trials strongly 
support the neumhormanal hypothesis. most of the dataare 
derived from studies usmg convening enzyme inhibitors. 
The hypothesis will be greatly strengthened if large-scale 
triols with betz.blockcrs and other neurohormonal antago- 
nist3 show favortble effects on cardiovascular morbidity and 
cardiac contractility) increase the mortality rate 126) and role for hemodynamic factors ii the progression of heart 
beta-blockers (which deprass cardiac contractilitv) prolonr failure. At Ieat one hemodvnnmicallv eR&ective drw ret+ 
life(50). lnterestmgly. lb; mechanisms by which th&eddrug~ men-a combination of hyhralazine -and isosorbid; diii- 
influence mortality may be similar. Both primarily affect the Irate-reduced the mortality rzte in the tist V-H&T study 
effect:, on myocardial cyclic AMP: beta-blocker; reduce 
total rr~;;&~~ iatc by &ir/i~g the risk of sudden death; 
intracellular cyclic AMP, whereas phosphodiesterase inhib- 
beta-blockers reduce this rusk (50). whereas phorphodiester- 
hors increase it. This parallelism suggests that the ncumbor- 
monal and biochemical effects of drugs are a more important 
are inhibitors increw it 153). ‘The two types of drugs also 
determinant of their influence on the niltuml htstory of heart 
fatlure than are their hemodyoamic actions. Similarly, the 
shore a common mode of action-thev bot!t exert profound 
d&&us et%cts of oifedipine and diltiazem appear to be 
explained more comp!e!ely by neurohrrmonal octisatton 
than by the negative inotropic effects of these calcium 
channel biockcrs 154). 
systems. Hence. it is like& that both neumhormonat and 
(IO). dnd the primary action of these two vasodilators is to 
hemodvnamic factors are imrmtant but indca‘ndent deter- 
minant~ of disease progress& in heart fail&. If this con- 
improve cardiac function (by reducing preload and afterload 
cept proves to be valid. it will be highly desirable that future 
dr& for heart failure exert both favorable hemodynamic 
and perhaps by increasing cardiac contractility [39.40]) and 
and ncurohormonal effects. 
not to decrease the activilv of endoanous neurohormonal 
Trials evaluating amlodipine, felodipine and tlosequinan. 
Such an approach is now being tested in several larg&cale. 
controlled. multicenter survival trials. .Amlodipitte and felt- 
dtpine are new calcium chmmi) blocking drugs that decrease 
(rather than increase) the activity of the svmpathetic nervous 
system (61.621. In contrast to other calcium channel block- 
ers. these drugs have been shown to lessen the symptoms 
inhibitors have produced disappointtng results. controlled and improve the exercise tolerance of patients with chronic 
!rds (55-58) have shown that long-term thenpy with dig. heart failure in controlled clinical studies (62.63). Two large 
^iiz rcL.c; sympwr,,a, p,u:ur~gs exerctse lulerance and scale lrials have been initiated to evaluate the effect of these 
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